Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
admin 20th July 2017 Uncategorised 0Sanofi’s top-selling Lantus is already contending with one copycat rival, and Merck & Co. just won FDA approval for another. Luckily for the $5 billion basal insulin, Merck’s new Lusduna Nexvue has to sit on the sidelines for now—and maybe for more than a year.
More: Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Source: fierce